ASK REDCHAT ANYTHING ABOUT ALTO NEUROSCIENCE INC.
Alto Neuroscience Inc. (NYSE: ANRO)
Listen to this Section
$26.66
+0.7550
(
+2.92% )
166.8K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| ALTO-300DetailsMajor depressive disorder |
Phase 2b |
| ALTO-100DetailsMajor depressive disorder |
Phase 2b |
| ALTO-101DetailsCognitive Impairment Associated with Schizophrenia |
Phase 2 |
| ALTO-203DetailsMajor depressive disorder |
Phase 2 |
|
| Open |
$26.66 |
| Previous Close |
$25.90 |
| Volume |
166.8K |
| Market Cap |
$1.01B |
| Day Range |
$25.69 - $27.47 |
| 52 Week Range |
$2.72 - $28.85 |
| Shares Outstanding |
38.87M |
| Change % |
+2.92% |
| Net Change |
▲ 0.7550 |
| Insider Ownership |
-0.01% |
| Exchange |
NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Year | 2024 |
| Country | United States |
| Underwriter | Jefferies, TD Cowen, Stifel, William Blair, Baird, more |
Insider Ownership Transactions
Total Amount Purchased:
594,204.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-07-11 |
Buy |
10681.00 |
Savitz Adam |
| 2024-05-22 |
Sale |
-188000.00 |
Hanley Jr. Michael Conick |
| 2024-04-01 |
Buy |
1600.00 |
Smith Nicholas Conrad |
| 2024-03-12 |
Sale |
-30574.00 |
Radhakrishnan Maha |
| 2024-03-06 |
Sale |
-251881.00 |
Apeiron Investment Group Ltd. |
| 2024-03-05 |
Sale |
-19153.00 |
Smith Nicholas Conrad |
| 2024-03-05 |
Sale |
-34711.00 |
Etkin Amit |
| 2024-03-05 |
Sale |
-73000.00 |
Savitz Adam |
| 2024-02-08 |
Buy |
1962995.00 |
Alpha Wave Global, LP |
| 2024-02-07 |
Buy |
7851.00 |
Savitz Adam |